Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: SystImmune secures first China approval for Iza-bren in Nasopharyngeal carcinoma Biokin Pharma has received NMPA approval for Iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC Gilead Sciences has received U.S. FDA approval for Trodelvy as a first-line treatment for adults with unresectable […]
Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: European Commission approves Trodelvy for first-line metastatic TNBC Gilead Sciences has received European Commission approval for Trodelvy as a first-line treatment for adult patients with unresectable locally […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: European Commission approves PADCEV as perioperative treatment for cisplatin-ineligible patients with resectable MIBC Astellas and Pfizer have received European Commission approval for PADCEV in combination with KEYTRUDA […]
Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: NMPA accepts Tecotabart Vedotin NDA for third-line CLDN18.2+ Gastric cancer The NDA for LM-302, a CLDN18.2-targeting antibody-drug conjugate developed by Sino Biopharmaceutical, has been accepted by China’s […]
Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: Lonza and InduPro announce licensing agreement to advance next-generation ADC therapeutics Lonza and InduPro have entered into a licensing agreement to advance next-generation antibody-drug conjugate therapeutics, providing […]
